Induction of neutralizing antibodies to Hendra and Nipah glycoproteins using a Venezuelan equine encephalitis virus in vivo expression system

Vaccine

Volumn 29, Issue 2, 2010, Pages 212-220

  Defang, Gabriel N ^a,b,c   Khetawat, Dimple ^b   Broder, Christopher C ^b   Quinnan Jr , Gerald V ^a  

^a Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c NAVAL MEDICAL RESEARCH CENTER   (United States)

Author keywords

Alphavirus replicon; Henipavirus; Vaccine

Indexed keywords

ALPHAVIRUS VACCINE; CROSS REACTING ANTIBODY; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL LINE; CONTROLLED STUDY; CROSS REACTION; DRUG EFFICACY; FEMALE; HENDRA VIRUS; HENIPAVIRUS INFECTION; HUMORAL IMMUNITY; IMMUNIZATION; IN VIVO STUDY; MOUSE; NIPAH VIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VENEZUELAN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ENCEPHALITIS VIRUS, VENEZUELAN EQUINE; FEMALE; GENE EXPRESSION; GENETIC VECTORS; HENDRA VIRUS; HENIPAVIRUS INFECTIONS; MICE; MICE, INBRED C3H; NIPAH VIRUS; VACCINES, SYNTHETIC; VIRAL PROTEINS;

EID: 78649706926     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.10.053     Document Type: Article

References (61)

1. Eaton B., et al. Hendra and Nipah viruses: different and dangerous. Nat Rev Microbiol 2006, 4(1):23-35.
2. Chua K.B., Goh K.J., Wong K.T., Kamarulzaman A., Tan P.S., Ksiazek T.G., et al. Fatal encephalitis due to Nipah virus among pig-farmers in Malaysia. Lancet 1999, 354(9186):1257-1259.
3. Chua K.B., Bellini W.J., Rota P.A., Harcourt B.H., Tamin A., Lam S.K., et al. Nipah virus, a newly emergent deadly paramyxovirus. Science 2000, 288:1432-1435.
4. Lam S.K., Chua K.B. Nipah virus encephalitis outbreak in Malaysia. Clin Infect Dis 2002, 34(2):S48-51.
5. Bishop K.A., Broder C.C. Hendra and Nipah: lethal zoonotic paramyxoviruses. Emerging infections 2008, 155-187. American Society for Microbiology, Washington, DC. W.M. Scheld, S.M. Hammer, J.M. Hughes (Eds.).
6. Nipah virus, fatal-Bangladesh (Dhaka). Pro-Med 2008, International Society for Infectious Diseases.
7. Nipah virus, fatal-Bangladesh (Faridpur). Pro-MED 2010, International Society for Infectious Diseases.
8. Gurley E.S., Montgomery J.M., Hossain M.J., Bell M., Azad A.K., Islam M.R., et al. Person-to-person transmission of Nipah virus in a Bangladeshi community. Emerg Infect Dis 2007, 13(7):1031-1037.
9. Harit A.K., Ichhpujani R.L., Gupta S., Gill K.S., Lal S., Ganguly N.K., et al. Nipah/Hendra virus outbreak in Siliguri, West Bengal, India in 2001. Indian J Med Res 2006, 123(4):553-560.
10. Homaira N., Rahman M., Hossain M.J., Epstein J.H., Sultana R., Khan M.S., et al. Nipah virus outbreak with person-to-person transmission in a district of Bangladesh, 2007. Epidemiol Infect 2010, 138(11):1630-1636.
11. Luby S.P., Rahman M., Hossain M.J., Blum L.S., Husain M.M., Gurley E., et al. Foodborne transmission of Nipah virus, Bangladesh. Emerg Infect Dis 2006, 12(12):1888-1894.
12. Field H., Young P., Yob J.M., Mills J., Hall L., Mackenzie J. The natural history of Hendra and Nipah viruses. Microbes Infect 2001, 3(4):307-314.
13. Westbury H.A. Hendra virus disease in horses. Rev Sci Tech 2000, 19(1):151-159.
14. Hanna J.N., McBride W.J., Brookes D.L., Shield J., Taylor C.T., Smith I.L., et al. Hendra virus infection in a veterinarian. Med J Aust 2006, 185(10):562-564.
15. Playford E.G., McCall B., Smith G., Slinko V., Allen G., Smith I., et al. Human Hendra virus encephalitis associated with equine outbreak, Australia, 2008. Emerg Infect Dis 2010, 16(2):219-223.
16. Chua K.B., Koh C.L., Hooi P.S., Wee K.F., Khong J.H., Chua B.H., et al. Isolation of Nipah virus from Malaysian Island flying-foxes. Microbes Infect 2002, 4(2):145-151.
17. Reynes J.M., Counor D., Ong S., Faure C., Seng V., Molia S., et al. Nipah virus in Lyle's flying foxes, Cambodia. Emerg Infect Dis 2005, 11(7):1042-1047.
18. Wacharapluesadee S., Lumlertdacha B., Boongird K., Wanghongsa S., Chanhome L., Rollin P., et al. Bat Nipah virus, Thailand. Emerg Infect Dis 2005, 11(12):1949-1951.
19. Crameri G., Wang L.F., Morrissy C., White J., Eaton B.T. A rapid immune plaque assay for the detection of Hendra and Nipah viruses and anti-virus antibodies. J Virol Methods 2002, 99(1-2):41-51.
20. Guillaume V., Contamin H., Loth P., Georges-Courbot M.C., Lefeuvre A., Marianneau P., et al. Nipah virus: vaccination and passive protection studies in a hamster model. J Virol 2004, 78(2):834-840.
21. Tamin A., Harcourt B.H., Ksiazek T.G., Rollin P.E., Bellini W.J., Rota P.A. Functional properties of the fusion and attachment glycoproteins of Nipah virus. Virology 2002, 296(1):190-200.
22. Weingartl H.M., Berhane Y., Caswell J.L., Loosmore S., Audonnet J.C., Roth J.A., et al. Recombinant Nipah virus vaccines protect pigs against challenge. J Virol 2006, 80(16):7929-7938.
23. Mungall B.A., Middleton D., Crameri G., Bingham J., Halpin K., Russell G., et al. Feline model of acute nipah virus infection and protection with a soluble glycoprotein-based subunit vaccine. J Virol 2006, 80(24):12293-12302.
24. Pushko P., Parker M., Ludwig G.V., Davis N.L., Johnston R.E., Smith J.F. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology 1997, 239(2):389-401.
25. Johnston R.E., Johnson P.R., Connell M.J., Montefiori D.C., West A., Collier M.L., et al. Vaccination of macaques with SIV immunogens delivered by Venezuelan equine encephalitis virus replicon particle vectors followed by a mucosal challenge with SIVsmE660. Vaccine 2005, 23(42):4969-4979.
26. Schultz-Cherry S., Dybing J.K., Davis N.L., Williamson C., Suarez D.L., Johnston R., et al. Influenza virus (A/HK/156/97) hemagglutinin expressed by an alphavirus replicon system protects chickens against lethal infection with Hong Kong-origin H5N1 viruses. Virology 2000, 278(1):55-59.
27. Balasuriya U.B., Heidner H.W., Davis N.L., Wagner H.M., Hullinger P.J., Hedges J.F., et al. Alphavirus replicon particles expressing the two major envelope proteins of equine arteritis virus induce high level protection against challenge with virulent virus in vaccinated horses. Vaccine 2002, 20(11-12):1609-1617.
28. Gupta S., Janani R., Bin Q. Characterization of HIV-gag-specific IFNg-expressing cells following protective mucosal immunization with alphavirus replicon particles. J Virol 2005, 79(11):7135-7145.
29. Dong M., Zhang P.F., Grieder F., Lee J., Krishnamurthy G., VanCott T., et al. Induction of primary virus-cross-reactive human immunodeficiency virus type 1-neutralizing antibodies in small animals by using an alphavirus-derived in vivo expression system. J Virol 2003, 77(5):3119-3130.
30. Quinnan G.V., Zhang P.F., Fu D.W., Dong M., Alter H.J. Expression and characterization of HIV type 1 envelope protein associated with a broadly reactive neutralizing antibody response. AIDS Res Hum Retroviruses 1999, 15(6):561-570.
31. Bossart K.N., Wang L.F., Flora M.N., Chua K.B., Lam S.K., Eaton B.T., et al. Membrane fusion tropism and heterotypic functional activities of the Nipah virus and Hendra virus envelope glycoproteins. J Virol 2002, 76(22):11186-11198.
32. Park E.J., Quinnan G.V. Both neutralization resistance and high infectivity phenotypes are caused by mutations of interacting residues in the human immunodeficiency virus type 1 gp41 leucine zipper and the gp120 receptor- and coreceptor-binding domains. J Virol 1999, 73(7):5707-5713.
33. Quinnan G.V., Yu X.F., Lewis M.G., Zhang P.F., Sutter G., Silvera P., et al. Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells. J Virol 2005, 79(6):3358-3369.
34. Bossart K.N., Crameri G., Dimitrov A.S., Mungall B.A., Feng Y.R., Patch J.R., et al. Receptor binding, fusion inhibition, and induction of cross-reactive neutralizing antibodies by a soluble G glycoprotein of Hendra virus. J Virol 2005, 79(11):6690-6702.
35. Leavitt M., Park E.J., Sidorov I.A., Dimitrov D.S., Quinnan G.V. Concordant modulation of neutralization resistance and high infectivity of the primary human immunodeficiency virus type 1 MN strain and definition of a potential gp41 binding site in gp120. J Virol 2003, 77(1):560-570.
36. Park E.J., Gorny M.K., Zolla-Pazner S., Quinnan G.V. A global neutralization resistance phenotype of human immunodeficiency virus type 1 is determined by distinct mechanisms mediating enhanced infectivity and conformational change of the envelope complex. J Virol 2000, 74(9):4183-4191.
37. Park E.J., Vujcic L.K., Anand R., Theodore T.S., Quinnan G.V. Mutations in both gp120 and gp41 are responsible for the broad neutralization resistance of variant human immunodeficiency virus type 1 MN to antibodies directed at V3 and non-V3 epitopes. J Virol 1998, 72(9):7099-7107.
38. Quinnan G.V., Zhang P.F., Fu D.W., Dong M., Alter H.J. Expression and characterization of HIV type 1 envelope protein associated with a broadly reactive neutralizing antibody response. AIDS Res Hum Retroviruses 1999, 15(6):561-570.
39. Quinnan G.V., Zhang P.F., Fu D.W., Dong M., Margolick J.B. Evolution of neutralizing antibody response against HIV type 1 virions and pseudovirions in multicenter AIDS cohort study participants. AIDS Res Hum Retroviruses 1998, 14(11):939-949.
40. Zhang P.F., Bouma P., Park E.J., Margolick J.B., Robinson J.E., Zolla-Pazner S., et al. A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response. J Virol 2002, 76(2):644-655.
41. Zhang P.F., Chen X., Fu D.W., Margolick J.B., Quinnan G.V. Primary virus envelope cross-reactivity of the broadening neutralizing antibody response during early chronic human immunodeficiency virus type 1 infection. J Virol 1999, 73(6):5225-5230.
42. Bonaparte M.I., Dimitrov A.S., Bossart K.N., Crameri G., Mungall B.A., Bishop K.A., et al. Ephrin-B2 ligand is a functional receptor for Hendra virus and Nipah virus. Proc Natl Acad Sci USA 2005, 102(30):10652-10657.
43. Bossart K.N., Broder C.C. Viral glycoprotein-mediated cell fusion assays using vaccinia virus vectors. Methods Mol Biol 2004, 269:309-332.
44. Bossart K.N., Mungall B.A., Crameri G., Wang L.F., Eaton B.T., Broder C.C. Inhibition of Henipavirus fusion and infection by heptad-derived peptides of the Nipah virus fusion glycoprotein. Virol J 2005, 2:57.
45. Nussbaum O., Broder C.C., Berger E.A. Fusogenic mechanisms of enveloped-virus glycoproteins analyzed by a novel recombinant vaccinia virus-based assay quantitating cell fusion-dependent reporter gene activation. J Virol 1994, 68(9):5411-5422.
46. Berger E.A., Nussbaum O., Broder C.C. HIV envelope glycoprotein/CD4 interactions: studies using recombinant vaccinia virus vectors. HIV: a practical approach 1995, vol. 2. p. 123-45.
47. Broder C.C., Berger E.A. Fusogenic selectivity of the envelope glycoprotein is a major determinant of human immunodeficiency virus type 1 tropism for CD4+ T-cell lines vs. primary macrophages. Proc Natl Acad Sci 1995, 92(19):9004-9008.
48. Pantaleo G., Koup R.A. Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. Nat Med 2004, 10:806-810.
49. Griffin D.E. Immune responses during measles virus infection. Curr Top Microbiol Immunol 1995, 191:117-134.
50. Zhu Z., Dimitrov A.S., Bossart K.N., Crameri G., Bishop K.A., Choudhry V., et al. Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies. J Virol 2006, 80(2):891-899.
51. McEachern J.A., Bingham J., Crameri G., Green D.J., Hancock T.J., Middleton D., et al. A recombinant subunit vaccine formulation protects against lethal Nipah virus challenge in cats. Vaccine 2008, 26(31):3842-3852.
52. Charles P.C., Brown K.W., Davis N.L., Hart M.K., Johnston R.E. Mucosal immunity induced by parenteral immunization with a live attenuated Venezuelan equine encephalitis virus vaccine candidate. Virology 1997, 228(2):153-160.
53. Grieder F.B., Davis N.L., Aronson J.F., Charles P.C., Sellon D.C., Suzuki K., et al. Specific restrictions in the progression of Venezuelan equine encephalitis virus-induced disease resulting from single amino acid changes in the glycoproteins. Virology 1995, 206(2):994-1006.
54. Davis N.L., Brown K.W., Johnston R.E. A viral vaccine vector that expresses foreign genes in lymph nodes and protects against mucosal challenge. J Virol 1996, 70(6):3781-3787.
55. Davis N.L., Caley I.J., Brown K.W., Betts M.R., Irlbeck D.M., McGrath K.M., et al. Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles. J Virol 2000, 74(1):371-378.
56. Pushko P., Bray M., Ludwig G.V., Parker M., Schmaljohn A., Sanchez A., et al. Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus. Vaccine 2000, 19(1):142-153.
57. Kinney R.M., Esposito J.J., Mathews J.H., Johnson B.J., Roehrig J.T., Barrett A.D., et al. Recombinant vaccinia virus/Venezuelan equine encephalitis (VEE) virus protects mice from peripheral VEE virus challenge. J Virol 1988, 62(12):4697-4702.
58. Jahrling P.B., Stephenson E.H. Protective efficacies of live attenuated and formaldehyde-inactivated Venezuelan equine encephalitis virus vaccines against aerosol challenge in hamsters. J Clin Microbiol 1984, 19(3):429-431.
59. Baker K.A., Dutch R.E., Lamb R.A., Jardetzky T.S. Structural basis for paramyxovirus-mediated membrane fusion. Mol Cell 1999, 3(3):309-319.
60. Brideau R.J., Oien N.L., Lehman D.J., Homa F.L., Wathen M.W. Protection of cotton rats against human parainfluenza virus type 3 by vaccination with a chimeric FHN subunit glycoprotein. J Gen Virol 1993, 74(3):471-477.
61. Drillien R., Spehner D., Kirn A., Giraudon P., Buckland R., Wild F., et al. Protection of mice from fatal measles encephalitis by vaccination with vaccinia virus recombinants encoding either the hemagglutinin or the fusion protein. Proc Natl Acad Sci 1988, 85(4):1252-1256.